{"a":[{"_":"Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech","$":{"href":"/biotech/novo-explores-macrocycles-potential-14b-cardiometabolic-pact-danish-biotech","hreflang":"en"}}]}

Summary

Novo has entered a $1.4 billion partnership with Danish biotech Orbis Medicines to explore oral macrocycle drugs for cardiometabolic indications, as part of its effort to strengthen its cardiometabolic portfolio.